Medpace Holdings, Inc. (NASDAQ:MEDP) Given Average Recommendation of “Hold” by Analysts

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have received a consensus rating of “Hold” from the seventeen analysts that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a sell recommendation, ten have given a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $490.8182.

A number of research analysts recently weighed in on MEDP shares. Barclays raised their price target on shares of Medpace from $485.00 to $525.00 and gave the company an “underweight” rating in a research report on Monday, December 15th. Truist Financial set a $555.00 target price on shares of Medpace in a research report on Monday, October 27th. Jefferies Financial Group boosted their target price on Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a research note on Tuesday, September 9th. BMO Capital Markets started coverage on Medpace in a report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 target price for the company. Finally, Robert W. Baird set a $613.00 price target on Medpace in a research report on Friday, October 24th.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $567.56 on Friday. The company has a 50-day moving average price of $579.62 and a 200-day moving average price of $481.39. The stock has a market capitalization of $15.99 billion, a P/E ratio of 39.69, a P/E/G ratio of 2.14 and a beta of 1.43. Medpace has a 1 year low of $250.05 and a 1 year high of $626.26.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. During the same quarter in the previous year, the business earned $3.01 EPS. The company’s quarterly revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities research analysts anticipate that Medpace will post 12.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Kevin M. Brady sold 3,000 shares of the stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $590.35, for a total value of $1,771,050.00. Following the sale, the chief financial officer directly owned 6,000 shares of the company’s stock, valued at approximately $3,542,100. This represents a 33.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the sale, the vice president owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 387,925 shares of company stock valued at $233,386,647 over the last ninety days. 20.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Medpace

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MEDP. Hsbc Holdings PLC raised its holdings in shares of Medpace by 157.5% in the 1st quarter. Hsbc Holdings PLC now owns 4,364 shares of the company’s stock valued at $1,296,000 after acquiring an additional 2,669 shares in the last quarter. OMERS ADMINISTRATION Corp increased its position in shares of Medpace by 39.6% in the first quarter. OMERS ADMINISTRATION Corp now owns 6,074 shares of the company’s stock worth $1,851,000 after purchasing an additional 1,724 shares during the last quarter. State of Wyoming raised its stake in Medpace by 24.6% in the first quarter. State of Wyoming now owns 365 shares of the company’s stock valued at $111,000 after purchasing an additional 72 shares in the last quarter. Canada Pension Plan Investment Board raised its stake in Medpace by 9.0% in the first quarter. Canada Pension Plan Investment Board now owns 47,400 shares of the company’s stock valued at $14,442,000 after purchasing an additional 3,900 shares in the last quarter. Finally, Magnetar Financial LLC bought a new stake in Medpace during the first quarter valued at approximately $2,666,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.